摘要
目的:分析青少年抑郁症并网络成瘾患者接受脑电生物反馈治疗的干预效果。方法:纳入2020年10月-2021年8月赣州市第三人民医院收治的青少年抑郁症并网络成瘾患者80例为研究对象,按随机数字表法分为对照组(40例)与研究组(40例)。对照组采用盐酸舍曲林片治疗,研究组采用脑电生物反馈疗法辅助盐酸舍曲林片治疗。比较治疗前及治疗2、4、8周后中文网络成瘾量表(CIAS-R)评分、汉密尔顿抑郁量表(HAMD-17)评分、汉密尔顿焦虑量表(HAMA)评分及安全性评估。结果:随着时间的延长,两组CIAS-R评分、HAMD-17评分、HAMA评分均呈下降趋势(P<0.05),且研究组治疗2、4、8周后CIAS-R评分、HAMD-17评分、HAMA评分相比对照组均更低(P<0.05)。研究组不良反应发生率低于对照组(P<0.05)。结论:对青少年抑郁症并网络成瘾患者采用脑电生物反馈疗法辅助盐酸舍曲林片治疗,可获得更佳治疗效果,更有助于改善抑郁焦虑症状,降低患者对网络的渴求度。
Objective:To analyze the intervention effect of EEG biofeedback therapy on adolescent depression with internet addiction.Method:A total of 80 adolescent patients with depression and internet addiction treated in Ganzhou Third People’s Hospital from October 2020 to August 2021 were included as the research objects.They were divided into control group(40 cases)and study group(40 cases)according to the random number table method.The control group was treated with Sertraline Hydrochloride Tablets,the study group was treated with EEG biofeedback therapy assisted with Sertraline Hydrochloride Tablets.The scores of Chinese internet addiction scale(CIAS-R),Hamilton depression scale(HAMD-17),Hamilton anxiety scale(HAMA)before treatment and 2,4 and 8 weeks after treatment and safety evaluation were compared.Result:With the extension of time,the CIAS-R scores,HAMD-17 scores and HAMA scores of the two groups showed a downward trend(P<0.05),and the CIAS-R score,HAMD-17 score and HAMA score of the study group were lower than those of the control group after 2,4 and 8 weeks of treatment(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusion:The EEG biofeedback therapy combined with Sertraline Hydrochloride Tablets for adolescent depression and internet addiction can achieve better therapeutic effect,help to improve depression and anxiety symptoms,and reduce patients’desire for the Internet.
作者
邱吉明
申璎
吴乔
袁其清
匡小龙
QIU Jiming;SHEN Ying;WU Qiao;YUAN Qiqing;KUANG Xiaolong(Ganzhou Third People’s Hospital,Jiangxi Province,Ganzhou 341000,China;不详)
出处
《中国医学创新》
CAS
2022年第21期146-149,共4页
Medical Innovation of China
基金
赣州市2021年指导性科技计划项目(GZ2021ZSF225)。
